Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company's lead product candidate, entinostat, is a selective HDAC inhibitor that has been evaluated in multiple clinical trials in combination with immune checkpoint inhibitors and targeted therapies. Syndax is also developing SNDX-5613, a highly selective and potent inhibitor of the Menin-MLL interaction, for the treatment of acute leukemias. The company is committed to improving the lives of cancer patients through the discovery and development of novel therapies.